BioSpace News Archive

First Known Clinical Report of Retinal Tissue Regeneration Following RPE Transplant Call Scheduled for June 8, 2020 with Therapeutic Area Experts to Discuss Findings

Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will provide a corporate update at the Jefferies 2020 Virtual Healthcare Conference

Treadwell Therapeutics, a clinical-stage biotechnology company developing novel therapeutics for highly aggressive cancers, today announced that members of the management team will provide a business overview and update at the Jefferies Virtual Healthcare Conference at 4:30 pm ET on Thursday, June 4, 2020. A live webcast of the presentation will be available through the Company’s website at www.treadwelltx.com . Following th

SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced today that it has re-financed its existing credit facility. Proceeds from the new $40 million, five-year term loan will be used to repay SI-BONE’s prior $40 million term loan obligation in its entirety. SI-BONE’s new term loan bears interest at a rate per annum equal to 9.40%

Rezolute, Inc. (“Rezolute” or “the Company”) (OCTQB:RZLT) recently announced that it has validated pharmacokinetic (PK) and pharmacodynamic (PD) models of its lead clinical asset, RZ358. Phase 2a data in adult and pediatric patients with congenital hyperinsulinism (HI) were shown to be predicted by the constructed models, and demonstrated that RZ358 raises glucose into a normal target range in a disease- and exposure-dependent manner,

Medial EarlySign™ (earlysign.com), a leader in AI-based clinical solutions to aid in the early detection and prevention of high-burden diseases, announced its recognition as an emerging healthcare AI company in a new KLAS® Research eTech Spotlight Report.

The first patients were treated as part of a clinical trial testing whether an antibody therapy can safely reduce COVID-19 disease severity. T

In response to the growing rate of food insecurity across the Commonwealth, Blue Cross Blue Shield of Massachusetts (“Blue Cross”) is partnering with local food relief nonprofits to provide nutritious meals to families in n

Arcutis Biotherapeutics, Inc . (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that Ayisha Jeter has joined the company as Vice President of Market Access. In this new role, Ms. Jeter will be responsible for Arcutis’ access and reimbursement efforts as the Compa

SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced its first international delivery of TPOXX® (tecovirimat), with 2,500 courses delivered to the Canadian Department of National Defence (CDND). On April 3, 2020, the Company previously announced that the CDND is expected to purchase u